Skip to main content
SpringerLink
Log in

Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

High-dose intravenous immunoglobulin (IVIG) is a well-established standard therapy for Kawasaki disease (KD) that reduces the risk of developing coronary artery aneurysms. On the other hand, some reports have recommended an alternative therapy with steroids for KD patients. In this study we investigated the anti-inflammatory effect of IVIG in comparison with dexamethasone at clinical doses in vitro. High-dose IVIG inhibited tumor necrosis factor-α (TNF-α)-induced activation of nuclear factor-κB (NF-κB) to a greater degree than dexamethasone in human monocytic U937 cells and human coronary arterial endothelial cells (HCAEC), but not in human T lymphocytic Jurkat cells. IVIG was more potent than dexamethasone in reducing the expression of CD16 (FcγRIII) in human monocytic THP-1 cells stimulated with lipopolysaccharide and in Jurkat cells stimulated with dimethyl sulfoxide. In HCAEC exposed to TNF-α, IVIG and dexamethasone inhibited interleukin-6 production to a similar degree, whereas the expression of E-selectin was inhibited more strongly by IVIG. Our results show that high-dose IVIG inhibits the activation of monocytes/macrophages and coronary arterial endothelial cells more strongly than that of T cells, whereas dexamethasone inhibits the activation of all three cell types. These findings suggest that IVIG or dexamethasone therapy should be chosen to match the types of cells that are activated during acute KD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Abe J, Kotzin BL, Jujo K, Melish ME, Glode MP, Kohsaka T, Leung DY (1992) Selective expansion of T cells expressing T-cell receptor variable regions Vβ2 and Vβ8 in Kawasaki disease. Proc Natl Acad Sci USA 89:4066–4070

    Article  PubMed  CAS  Google Scholar 

  • Ariga S, Koga M, Takahashi M, Ishihara T, Matsubara T, Furukawa S (2001) Maturation of macrophages from peripheral blood monocytes in Kawasaki disease: immunocytochemical and immunoelectron macroscopic study. Pathol Int 51:257–263

    Article  PubMed  CAS  Google Scholar 

  • Baeuerle PA, Henkel T (1994) Function and activation of NF-κB in the immune system. Annu Rev Immunol 12:141–179

    PubMed  CAS  Google Scholar 

  • Baldwin AS Jr (1996) The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14:649–683

    Article  PubMed  CAS  Google Scholar 

  • Barron K, DeCunto C, Montalvo J, Orson F, Lewis D (1988) Abnormalities of immunoregulation in Kawasaki syndrome. J Rheumatol 15:1243–1249

    PubMed  CAS  Google Scholar 

  • Boehme MW, Schmitt WH, Youinou P, Stremmel WR, Gross WL (1996) Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener’s granulomatosis and other systemic vasculitides. Am J Med 101:387–394

    Article  PubMed  CAS  Google Scholar 

  • Dale RC, Saleem MA, Daw S, Dillon MJ (2000) Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr 137:723–726

    Article  PubMed  CAS  Google Scholar 

  • Fujiwara H, Hamashima Y (1978) Pathology of the heart in Kawasaki disease. Pediatrics 61:100–107

    PubMed  CAS  Google Scholar 

  • Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, Kato H, Yabuta K (1988) Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 48:247–251

    Article  PubMed  CAS  Google Scholar 

  • Furukawa S, Matsubara T, Jujoh K, Sasai K, Nakachi S, Sugawara T, Yabuta K, Kato H (1990) Reduction of peripheral blood macrophages/monocytes in Kawasaki disease by intravenous gammaglobulin. Eur J Pediatr 150:43–47

    Article  PubMed  CAS  Google Scholar 

  • Furukawa S, Matsubara T, Tsuji K, Motohashi T, Okumura K, Yabuta K (1991) Serum soluble CD4 and CD8 levels in Kawasaki disease. Clin Exp Immunol 86:134–139

    Article  PubMed  CAS  Google Scholar 

  • Furukawa S, Imai K, Matsubara T, Yone K, Yachi A, Okumura K, Yabuta K (1992a) Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease. Arthritis Rheum 35:672–677

    Article  PubMed  CAS  Google Scholar 

  • Furukawa S, Matsubara T, Yabuta K (1992b) Mononuclear cell subsets and coronary artery lesions in Kawasaki disease. Arch Dis Child 67:706–708

    Article  PubMed  CAS  Google Scholar 

  • Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, Yabuta K (1992c) Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-α and interleukin 6 in serum. Eur J Pediatr 151:44–47

    Article  PubMed  CAS  Google Scholar 

  • Furukawa S, Matsubara T, Tsuji K, Okumura K, Yabuta K (1993) Transient depletion of T cells with bright CD11a/CD18 expression from peripheral circulation during acute Kawasaki disease. Scand J Immunol 37:377–380

    Article  PubMed  CAS  Google Scholar 

  • Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K (1994) Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr 124:721–725

    Article  PubMed  CAS  Google Scholar 

  • Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, Tamura T, Hirose O, Manabe Y, Yokoyama T, Kawarano M, Baba K, Baba K, Mori C (1984) High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 2:1055–1058

    Article  PubMed  CAS  Google Scholar 

  • Hirao J, Hibi S, Andoh T, Ichimura T (1997) High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int Arch Allergy Immunol 112:152–156

    Article  PubMed  CAS  Google Scholar 

  • Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, Matsubara T, Hayashi T, Furukawa S (2001) NF-κB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 99:373–377

    Article  PubMed  CAS  Google Scholar 

  • Ichiyama T, Ueno Y, Isumi H, Niimi A, Matsubara T, Furukawa S (2004a) Intravenous immunoglobulin inhibits NF-κB activation and affects Fcγ receptor expression in monocytes/macrophages. Naunyn-Schmiedebergs Arch Pharmacol 369:428–433

    Article  PubMed  CAS  Google Scholar 

  • Ichiyama T, Ueno Y, Isumi H, Niimi A, Matsubara T, Furukawa S (2004b) An immunoglobulin agent (IVIG) inhibits NF-κB activation in cultured endothelial cells of coronary artery in vitro. Inflamm Res 53:253–256

    Article  PubMed  CAS  Google Scholar 

  • Katayama K, Matsubara T, Fujiwara M, Koga M, Furukawa S (2000) CD14+CD16+ monocyte subpopulation in Kawasaki disease. Clin Exp Immunol 121:566–570

    Article  PubMed  CAS  Google Scholar 

  • Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R (1996) Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 94:1379–1385

    PubMed  CAS  Google Scholar 

  • Kawasaki T, Kosaki F, Ogawa S, Shigemitsu I, Yanagawa H (1974) A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 54:271–276

    PubMed  CAS  Google Scholar 

  • Kim DS, Lee KY (1994) Serum soluble E-selectin levels in Kawasaki disease. Scand J Rheumatol 23:283–286

    Article  PubMed  CAS  Google Scholar 

  • Koga M, Ishihara T, Takahashi M, Umezawa Y, Furukawa S (1998) Activation of peripheral blood monocytes and macrophages in Kawasaki disease: ultrastructural and immunocytochemical investigation. Pathol Int 48:512–517

    PubMed  CAS  Google Scholar 

  • Lang GA, Silverman ED, Laxer RM, Lau AS (1989) Spontaneous tumor necrosis factor production in Kawasaki disease. Lancet 2:1298–1302

    Article  Google Scholar 

  • Leung DYM, Chu ET, Wood N, Grady S, Meade R, Geha RS (1983) Immunoregulatory T cell abnormalities in mucocutaneous lymph node syndrome. J Immunol 130:2002–2004

    PubMed  CAS  Google Scholar 

  • Leung DY, Burns JC, Newburger JW, Geha RS (1987) Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 79:468–472

    Article  PubMed  CAS  Google Scholar 

  • Leung DYM, Cotran RS, Kurt-Johnes E, Burns JC, Newburger JW, Pober JS (1989) Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. J Pediatr 115:939–943

    Article  Google Scholar 

  • Lin SY, Kinet JP (2001) Giving inhibitory receptors a boost. Science 291:445–446

    Article  PubMed  CAS  Google Scholar 

  • Lin CY, Lin CC, Hwang B, Chiang B (1992) Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor α among patients with Kawasaki disease. J Pediatr 121:924–926

    Article  PubMed  CAS  Google Scholar 

  • Matsubara T, Katayama K, Matsuoka T, Fujiwara M, Koga M, Furukawa S (1999) Decreased interferon-gamma (IFN-γ)-producing T cells in patients with acute Kawasaki disease. Clin Exp Immunol 116:554–557

    Article  PubMed  CAS  Google Scholar 

  • Matsubara T, Ichiyama T, Furukawa S (2005) Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol 141:381–387

    Article  PubMed  CAS  Google Scholar 

  • Maury CP, Salo E, Pelkonen P (1988) Circulating interleukin-1β in patients with Kawasaki disease. N Engl J Med 319:1670–1671

    Article  PubMed  CAS  Google Scholar 

  • Morris HG (1983) Pharmacology of corticosteroids in asthma. In: Middleton Jr E, Reed CE, Ellis EF (eds) Allergy—principles and practice. Mosby, St. Louis, pp 593–600

    Google Scholar 

  • Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME (1986) The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341–347

    Article  PubMed  CAS  Google Scholar 

  • Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, Mason WH, Meissner HC, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639

    Article  PubMed  CAS  Google Scholar 

  • Okada Y, Shinohara M, Kobayashi T, Inoue Y, Tomomasa T, Kobayashi T, Morikawa A, Gunma Kawasaki Disease Study Group (2003) Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 143:363–367

    Article  PubMed  CAS  Google Scholar 

  • Radeke HH, Janssen-Graalfs I, Sowa EN, Chouchakova N, Skokowa J, Loscher F, Schmidt RE, Heeringa P, Gessner JE (2002) Opposite regulation of type II and III receptors for immunoglobulin G in mouse glomerular mesangial cells and in the induction of anti-glomerular basement membrane (GBM) nephritis. J Biol Chem 277:27535–27544

    Article  PubMed  CAS  Google Scholar 

  • Sánchez-Mejorada G, Rosales C (1998) Fcγ receptor-mediated mitogen-activated protein kinase activation in monocytes is independent of Ras. J Biol Chem 273:27610–276109

    Article  PubMed  Google Scholar 

  • Sugawara T, Hattori S, Hirose S, Furukawa S, Yabuta K, Shirai T (1987) Immunopathology of the skin lesions of Kawasaki disease. In: Schulman ST (ed) Kawasaki disease. Liss, New York, pp 185–192

    Google Scholar 

  • Sundel RP, Baker AL, Fulton DR, Newburger JW (2003) Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 142:611–616

    Article  PubMed  CAS  Google Scholar 

  • Terai M, Kohno Y, Niwa K, Toba T, Sakurai N, Nakajima H (1987) Imbalance among T-cell subsets in patients with coronary arterial aneurysms in Kawasaki disease. Am J Cardiol 60:555–559

    Article  PubMed  CAS  Google Scholar 

  • Terai M, Kohno Y, Namba M, Umemiya T, Niwa K, Nakajima H, Mikata A (1990) Class II major histocompatibility antigen expression on coronary arterial endothelium in a patient with Kawasaki disease. Hum Pathol 21:231–234

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Yamaguchi University School of Medicine, 1-1-1 Minami-kogushi, Ube, 755-8505, Yamaguchi, Japan

    Haruyuki Makata, Takashi Ichiyama, Ryutaro Uchi, Tsuyoshi Takekawa, Tomoyo Matsubara & Susumu Furukawa

Authors
  1. Haruyuki Makata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Ichiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryutaro Uchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsuyoshi Takekawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoyo Matsubara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Susumu Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takashi Ichiyama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Makata, H., Ichiyama, T., Uchi, R. et al. Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease. Naunyn-Schmied Arch Pharmacol 373, 325–332 (2006). https://doi.org/10.1007/s00210-006-0084-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-006-0084-z

Keywords

Search

Navigation